Communications medicine最新文献

{"title":"Multi-omics integration of proteomics and metabolomics in pediatric health and disease.","authors":"Andrei M Matusa, David Tweddell, Mark Daley, David B O'Gorman, Douglas D Fraser","doi":"10.1038/s43856-026-01934-7","DOIUrl":"10.1038/s43856-026-01934-7","url":null,"abstract":"<p><p>Personalized medicine is essential for delivering efficacious care to children, yet pediatric-specific research and treatment guidelines lag behind those for adults. Multi-omics integration may offer clinicians biologically grounded patient stratification beyond traditional clinical biomarkers. While this approach holds promise for advancing precision medicine, it remains incompletely validated, and significant barriers to routine clinical implementation persist. In this review, we discuss practical considerations for integrating proteomics and metabolomics in pediatric multi-omics research. We describe popular code- and web-based tools, and recent examples of multi-omics studies in pediatric cohorts, concluding with current challenges and future outlooks for integrative multi-omics studies.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"6 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13620128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149076820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics of asymmetric hearing loss in children from a large pediatric cohort.","authors":"Laura E Hahn, Mario Fleischer, Friederike Wohlfarth, Jonas Althaus, Dirk Mürbe, Claudia Männel, Anke Hirschfelder","doi":"10.1038/s43856-026-01923-w","DOIUrl":"10.1038/s43856-026-01923-w","url":null,"abstract":"<p><strong>Background: </strong>Asymmetric hearing loss (HL) is a common pediatric condition, characterized by differences in HL severity between both ears. Anamnestic and audiologic profiles of affected children are sparse, hindering development of evidence-based clinical guidelines.</p><p><strong>Methods: </strong>Clinical characteristics for children with bi- and unilateral asymmetric HL were retrospectively obtained from a register of children with permanent HL in Germany. Cohorts were stratified by laterality (uni-/bilateral) and presence of comorbidities (with/without). Between-group differences were assessed using absolute standardized mean differences.</p><p><strong>Results: </strong>Here we show, across uni- and bilateral groups, family history of HL is reported for approximately 25% and comorbidities for 40%-50% of children. Children with bilateral HL have a higher proportion of pre-/perinatal risk factors (e.g., hypoxia, artificial ventilation) than children with unilateral HL. Hereditary HL is more common in children with bilateral HL, whereas unexplained causes of HL is more frequent in unilateral cases. Sensorineural HL is predominant across groups; conductive or combined HL occurs more often in children with unilateral HL and comorbidities. Sloping and flat audiogram configurations are common across groups, though many children also exhibit other shapes. Notably, 60% of children with bilateral HL present different audiogram configurations in their left and right ears.</p><p><strong>Conclusion: </strong>Children with asymmetric HL represent a heterogeneous population with diverse clinical characteristics. This study highlights the need for comprehensive audiologic examination and tailored technical intervention. Bilateral asymmetries may pose greater clinical challenges compared to unilateral cases, due to higher incidence of comorbidities and risk factors as well as the high incidence of inter-aural differences in audiogram configurations.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"6 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13614944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149066549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author Correction: A data-centric approach to detecting and mitigating demographic bias in pediatric mental health text.","authors":"Julia Ive, Paulina Bondaronek, Vishal Yadav, Daniel Santel, Tracy Glauser, Jeffrey R Strawn, Greeshma Agasthya, Jordan Tschida, Sanghyun Choo, Mayanka Chandrashekar, Anuj J Kapadia, John Pestian","doi":"10.1038/s43856-026-01742-z","DOIUrl":"10.1038/s43856-026-01742-z","url":null,"abstract":"","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"6 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13614964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149066531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional antibody responses and protection against symptomatic dengue.","authors":"Caroline Lin Lin Chua, Hoa Thi My Vo, Carla Bianca Luena Victorio, Vinit Upasani, Bryan Ju Min Yap, Andrew Teo","doi":"10.1038/s43856-026-01922-x","DOIUrl":"10.1038/s43856-026-01922-x","url":null,"abstract":"<p><p>Exposure to dengue virus (DENV) triggers the development of anti-viral antibodies that may contribute to either protection or disease progression. Antibodies exist in different isotypes and subtypes, with diverse specificities and functions. IgG antibodies are produced during primary and secondary DENV infections, where they play a role central role in mediating protective immunity, and may also contribute to antibody-dependent enhancement in a secondary heterotypic infection. Although IgG antibodies are widely recognised as key mediators of protective immune responses during DENV infection, antibody specificities, types and functions that reliably correlate with protection remain unclear. A better understanding of anti-DENV antibodies and their roles in protection against symptomatic dengue is essential especially in guiding the design of dengue vaccines. In this review, antibody functions and effector mechanisms in DENV infection are discussed, with a focus on naturally acquired immunity and neutralising antibody responses following vaccination. In addition, current knowledge gaps in antibody functions during DENV infection will be highlighted.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"6 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13598121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149027240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author Correction: Safety and pharmacokinetics of the non-hormonal male contraceptive YCT-529.","authors":"Nadja Mannowetz, Stewart W McCallum, Sharan Sidhu, Karen H Mena, Eric P Ruby, Ramiro Castro-Santamaria, Emily Dodds, Dennis Henderson, Gareth Whitaker, Heather Wright, Sarah Beaudoin, Gunda I Georg, Akash Bakshi","doi":"10.1038/s43856-026-01894-y","DOIUrl":"10.1038/s43856-026-01894-y","url":null,"abstract":"","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"6 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13594152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149018883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Naive T cell-depleted hematopoietic stem cell transplantation to minimize immunosuppression after solid organ transplantation: case report.","authors":"Antonio Pérez-Martínez, Cristina Aguirre-Portolés, Carmen Mestre-Durán, Nidia Monserrat Arreola, Bárbara Pascual-Miguel, Pablo Stringa, María Ovidia López Oliva, Rodrigo Papa-Gobbi, Rocío González-Sacristán, Mercedes Gasior, Antonio Marcos, Raquel de Paz, José María Alonso, Karima Al-Akioui-Sanz, Lidia Pertíñez, Cristina Ferreras, Raquel Tobes, Eduardo Pareja, Antonio Balas, José Luis Vicario, Belén Estébanez, Marta Muñoz Fernández de Legaria, Esther Ramos-Boluda, Sandra Sanz, Carlos Jiménez, Onys Camps, Ane M Andrés, Francisco Hernández-Oliveros","doi":"10.1038/s43856-026-01906-x","DOIUrl":"10.1038/s43856-026-01906-x","url":null,"abstract":"<p><strong>Background: </strong>Solid organ transplantation (SOT) outcomes remain suboptimal due to graft rejection, drug-related complications and comorbidities. Hematopoietic stem cell transplantation (HSCT) has been explored to induce chimerism and tolerance, reducing reliance on immunosuppression.</p><p><strong>Methods: </strong>We report two patients who, post-SOT, received non-myeloablative conditioning followed by a naïve T-cell-depleted HSCT and memory T-cell (CD45RA⁻) donor lymphocyte infusions under a compassionate use program. Mixed lymphocyte reaction (MLR) experiments performed 41 (Patient #1) and 31 (Patient #2) months after SOT/HSCT and TCRβ deep Illumina sequencing, together with clonotype frequency analysis, were used to identify donor-reactive T-cell clonotypes.</p><p><strong>Results: </strong>Both patients were maintained in minimal immunosuppression with no signs of rejection more than 5 years after the SOT/HSCT. Recipient cells resulted hyporesponsive to donor and third-party cells, yet retained reactivity to CMV infection. TCRβ profiling provided an overview of the lymphocyte subpopulations before and after transplantation. Donor-reactive clonotypes potentially associated with rejection were identified pre-HSCT and monitored after this procedure.</p><p><strong>Conclusions: </strong>Our clinical strategy is a feasible, safe approach to induce transient mixed chimerism and may support minimization of immunosuppression following SOT. Despite considerable heterogeneity between patients - affected organ, donor source (deceased/living), and HLA compatibility (fully mismatched/matched sibling) -, we consider our findings to provide a valuable foundation for development of a clinical trial recently started at our hospital: A phase I, single-center, open-label trial to assess safety and tolerability of delayed infusion of a naïve T-cell-depleted hematopoietic graft and memory T-lymphocytes in recipients of solid organ transplantation (NCT06997471).</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"6 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13594325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149018847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phosphorylated tau 217 in young adults with Down syndrome and Down syndrome regression disorder.","authors":"Jonathan D Santoro, Sara Abdel-Latif, Abhik K Banerjee, Hannah Mager, Mackenzie Silverman, Lilia Kazerooni, Samuel T Otey, Mariam M Yousuf, Maeve C Lucas, Zinayida Schlachetzki, Robert A Rissman, Michael S Rafii","doi":"10.1038/s43856-026-01921-y","DOIUrl":"10.1038/s43856-026-01921-y","url":null,"abstract":"<p><strong>Background: </strong>Down syndrome regression disorder (DSRD) causes a rapid loss of cognitive, behavioral, and daily living skills, usually in adolescents and young adults with Down syndrome. Because people with Down syndrome have a high lifetime risk of Alzheimer's disease, we examined whether DSRD is associated with an Alzheimer-related pattern of tau pathology.</p><p><strong>Methods: </strong>In this prospective, single-center study, we measured plasma phosphorylated tau-217 (p-tau217), a blood marker of Alzheimer pathology, in 132 participants: 48 with DSRD, 39 with Down syndrome without regression (DSwR), and 45 neurodevelopmental controls. We compared p-tau217 concentrations across groups and examined relationships with demographic factors, medical conditions, treatment status, and diagnostic test abnormalities.</p><p><strong>Results: </strong>Median p-tau217 concentrations were similar in the DSRD (0.082 pg/mL), DSwR (0.084 pg/mL), and neurodevelopmental control (0.080 pg/mL) groups (overall comparison, p  =  0.57). Pairwise comparisons and models accounting for demographic and clinical factors also showed no statistically significant group differences. Among participants with DSRD, p-tau217 was not associated with treatment status or abnormalities on brain-wave testing, neuroimaging, or cerebrospinal fluid analysis. No clinical or demographic factor remained associated with p-tau217 after accounting for the number of analyses performed.</p><p><strong>Conclusions: </strong>These findings provide no evidence of a group-level Alzheimer-related p-tau217 elevation in young people with DSRD and support DSRD as a condition distinct from Alzheimer's disease. However, a single blood measurement cannot exclude Alzheimer pathology in an individual. Longitudinal studies using several complementary biomarkers are needed.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"6 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13680608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author Correction: Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiforme.","authors":"Ramcharan Singh Angom, Hari Krishnareddy Rachamala, Naga Malleswara Rao Nakka, Vijay Sagar Madamsetty, Paola Suarez-Meade, Beatriz I Fernandez-Gil, Tanmay Kulkarni, Raegan M Weil, Shamit Dutta, Enfeng Wang, Santanu Bhattacharya, Krishnendu Pal, Alfredo Quinones-Hinojosa, Debabrata Mukhopadhyay","doi":"10.1038/s43856-026-01895-x","DOIUrl":"10.1038/s43856-026-01895-x","url":null,"abstract":"","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"6 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13594117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149018845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integration of multiple perspectives to understand the left ventricular pressure-volume relationship.","authors":"Giovanni Tonti, Gianni Pedrizzetti, Alessandro Salustri","doi":"10.1038/s43856-026-01901-2","DOIUrl":"10.1038/s43856-026-01901-2","url":null,"abstract":"<p><p>For more than a century, the pressure-volume loop has offered a simple and elegant way to show how the heart pumps blood. In one picture, it summarizes how the heart fills, contracts, and ejects blood. However, this simplicity has a limitation: the loop treats the heart as if it were a single, uniform chamber. Therefore, it cannot reveal many important biological and mechanical processes that influence how the heart truly works. This helps explain why some patients develop symptoms or early signs of heart problems even when their pressure-volume measurements look completely normal. In this Perspective, we describe the pressure-volume relationship not as a stand-alone measure but as an emergent phenotype - the visible \"end result\" of many processes happening at different levels. Beneath the loop are the molecular and cellular mechanisms that control how heart muscle contracts and relaxes. Beyond the loop are differences in how various regions of the heart function, the organised patterns of blood flow inside the ventricle, and the continuous interaction between the heart and the rest of the circulatory system. We discuss how advanced imaging, flow visualization techniques, and computational modelling can add depth to pressure-volume analysis, revealing mechanisms that global, chamber-level measurements cannot show. Seen this way, the familiar loop becomes a window into an individual patient's underlying biology, helping clinicians diagnose problems earlier and more accurately. This approach may help reveal the true mechanisms behind seemingly normal pressure-volume loops and support more precise, targeted treatments.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"6 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13582966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148984334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials.","authors":"Anne Sophie Platzbecker, Katharina Zoldan, Dominic Brauer, Philipp Kiewe, Daniel Sasca, Katja Sockel, Thomas Illmer, Aristoteles Giagounidis, Daniel Nowak, Kathrin Rieger, Friederike Wortmann, Katharina Götze, Martin Schmidt-Hieber, Karin Mayer, Ursula Vehling-Kaiser, Rudolf Weide, Stefan Mahlmann, Jens Przybilla, Susanne Melzer, Michael Cross, Marie Schneider, Dirk Hasenclever, Klaus H Metzeler, Uwe Platzbecker","doi":"10.1038/s43856-026-01885-z","DOIUrl":"10.1038/s43856-026-01885-z","url":null,"abstract":"<p><strong>Background: </strong>Dysregulated innate immune signaling promotes inflammatory suppression of hematopoietic stem and progenitor cell function, contributing to ineffective erythropoiesis in myelodysplastic neoplasms (MDS). The phase 2, open-label CANFIRE and LUCAS trials aimed to determine the efficacy and safety of canakinumab or emavusertib, respectively, in patients with lower-risk MDS (LR-MDS) or myelodysplastic/myeloproliferative neoplasms (MDS/MPN).</p><p><strong>Methods: </strong>Patients in CANFIRE were refractory, intolerant to, or ineligible for erythropoiesis-stimulating agent (ESA) treatment and received canakinumab 200 mg subcutaneously every 21 days for up to eight cycles within the first six months of treatment. Patients in LUCAS were either refractory or intolerant to ESAs (cohort A) or ESA-naïve with serum erythropoietin levels >200 U/L (cohort B); all patients received emavusertib 200-300 mg orally twice daily for 21 days in up to four 28-day cycles. The primary endpoint for both trials was hematologic improvement-erythroid per International Working Group 2018 criteria at the end of the planned treatment period. CANFIRE was registered at ClinicalTrials.gov (NCT05237713; registered January 21, 2022). LUCAS was registered in the EU Clinical Trials Register (EudraCT 2020-003986-20; registered March 15, 2021) and at ClinicalTrials.gov (NCT05178342; registered November 2, 2021).</p><p><strong>Results: </strong>Here we show that of 11 patients enrolled in CANFIRE and 36 patients enrolled in LUCAS, no patients in either trial achieved the primary endpoint. Canakinumab treatment was well-tolerated, with no reported serious adverse events (SAEs) and no patients died in the CANFIRE trial. In the LUCAS trial, 15 patients reported SAEs, and four patients died. CANFIRE and LUCAS were terminated early due to inadequate patient recruitment and after a pre-planned interim futility analysis, respectively.</p><p><strong>Conclusions: </strong>Inhibition of IL-1β or IRAK4 signaling with canakinumab or emavusertib did not result in hematologic improvement in patients with LR-MDS.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"6 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13583006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148984362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}